ASBP

Aspire Biopharma Holdings, Inc. (ASBP) Economic Moat Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Scale Market Position

ASBP remains a micro-cap with a market cap of about $1.0M, limiting evidence of durable scale advantages.

Revenue per share is only $0.09 TTM, indicating an extremely small operating base.

Pricing Power Margins

Gross margin is only 18.3% TTM, while EBIT margin is deeply negative at -64.7%, showing weak pricing power and poor operating leverage.

Net profit margin is -113.1% TTM, reinforcing that the business is not converting sales into durable profits.

Customer Stickiness Retention

No fresh evidence indicates recurring revenue, contractual lock-in, or other retention advantages.

The extremely low asset turnover and working-capital inefficiency suggest a business without clear operating stickiness.

Intangible Assets Switching Costs

No material evidence of patents, brands, or proprietary assets supporting a moat.

Intangibles are 0% of total assets, which does not support meaningful intangible-driven defensibility.

Cost Advantage Operating Efficiency

Operating efficiency remains poor, with operating cash flow sales ratio at -73.6% and working capital turnover at 0.01x.

Inventory and payables days are extremely elevated, suggesting inefficient operations rather than a structural cost advantage.

Network Effects Ecosystem

No evidence of network effects, platform dynamics, or ecosystem lock-in in the available data.

The company’s tiny scale and lack of revenue momentum do not indicate a self-reinforcing moat.

Financial Strength Resilience

Liquidity is strong, with a current ratio of 8.0x and cash ratio of 7.2x, which supports near-term resilience.

The balance sheet shows no debt, but profitability and cash generation remain weak, limiting long-term moat durability.

Moat Durability Outlook

The current data still does not show a durable economic moat, as profitability, scale, and efficiency remain very weak.

Strong liquidity provides survival support, but it does not by itself create competitive advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →